NCT07604883 · NOT YET RECRUITING
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
This observational study is looking for molecular clues in blood, urine, and stool that could help doctors tell Parkinson's disease apart from rarer movement disorders like Multiple System Atrophy and Progressive Supranuclear Palsy. No treatments are given. Participants are followed for 12 to 18 months and donate biological samples for analysis. There is no assigned phase — this is early discovery research, not a drug test.
You may qualify if
- Patients with suspected neurodegenerative parkinsonism in the course of Parkinson's disease (PD) or atypical parkinsonian syndromes (APS), defined according to the MDS 2015 criteria as bradykinesia accompanied by at least one additional symptom: rigidity and/or resting tremor.
- Age between 40 and 80 years.
- Written informed consent for participation in the study.
- Duration of parkinsonian symptoms shorter than 3 years.
- Abnormal DaTscan result confirming presynaptic dopaminergic neuronal degeneration.
You're excluded if
- Lack of consent to participate in the study.
- Secondary or drug-induced parkinsonism.
- Other central nervous system (CNS) disorders (e.g., neoplastic or vascular processes) that could account for the symptoms.
- Active malignancy, infection, or autoimmune inflammatory disease.
- Severe systemic diseases (advanced heart failure NYHA class III-IV, poorly controlled diabetes mellitus, renal failure with GFR ≤ 60, or hepatic failure).
- Presence of a known monogenic mutation causing parkinsonism according to OMIM classification.
- Antibiotic therapy or use of probiotics within 3 months prior to the study visit.
- Pregnancy or breastfeeding.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-22